XML 45 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurement (Details 1) (CyDex, USD $)
In Millions, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Credit Derivatives [Line Items]    
Amount Of revenue for contingent consideration 15lgnd_AmountOfRevenueForContingentConsideration  
Contingent Consideration
    
Credit Derivatives [Line Items]    
Revenue volatility (percent) 25.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember		 25.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
Average of probability of commercialization (percent) 81.00%lgnd_FairValueInputsAverageOfProbabilityOfCommercialization
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember		 68.00%lgnd_FairValueInputsAverageOfProbabilityOfCommercialization
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
Sales beta (decimal) 0.60lgnd_FairValueInputsSalesBeta
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember		 0.60lgnd_FairValueInputsSalesBeta
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
Credit rating (non-numeric) B BBB
Equity risk premium (percent) 6.00%us-gaap_FairValueInputsControlPremium
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember		 6.00%us-gaap_FairValueInputsControlPremium
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
Minimum | Contingent Consideration
    
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing 17.2lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		 [1] 4.2lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		 [1]
Maximum | Contingent Consideration
    
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing 17.3lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		 [1] 19.8lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
/ us-gaap_BusinessAcquisitionAxis
= lgnd_CydexPharmaceuticalsIncMember
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_ContingentConsiderationClassifiedAsEquityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		 [1]
[1] Revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement.